Myasthenia Gravis

Myasthenia Gravis – High‑Yield Study Guide for Medical Students

Definition

Myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction characterized by fluctuating, fatigable skeletal muscle weakness, most commonly affecting ocular, bulbar, and proximal limb muscles. Autoantibodies target components of the postsynaptic membrane (most often the acetylcholine receptor), impairing neuromuscular transmission and leading to reduced strength with repeated use. [1](https://europepmc.org/article/MED/41607837) [3](https://europepmc.org/article/MED/41462932)

Epidemiology

MG is a rare disease but is the most common autoimmune disorder affecting the neuromuscular junction. It has a bimodal age distribution, with early-onset disease more frequent in young women and late-onset disease more frequent in older men. The overall prevalence has increased over recent decades, likely due to improved recognition, diagnostic testing, and longer survival. [3](https://europepmc.org/article/MED/41462932)

Key epidemiologic points include:

• Prevalence: Low but rising; MG is considered a rare disease yet encountered regularly in neurology practice. [3](https://europepmc.org/article/MED/41462932)
• Age distribution: Early-onset MG typically in women <40 years; late-onset MG more common in men >60 years.
• Association with thymic pathology: High frequency of thymic hyperplasia in early-onset and thymoma in a subset of patients.

Pathophysiology

MG is primarily mediated by autoantibodies targeting proteins in the postsynaptic membrane at the neuromuscular junction. This disrupts synaptic transmission, leading to reduced safety factor for neuromuscular transmission and fatigable weakness. [1](https://europepmc.org/article/MED/41607837) [3](https://europepmc.org/article/MED/41462932)

• Autoantibodies:
  • Anti–acetylcholine receptor (AChR) antibodies are the most common and best-characterized, causing receptor internalization, complement-mediated damage of the postsynaptic membrane, and functional receptor blockade.
  • Anti–MuSK (muscle-specific kinase) and other antibodies (e.g., LRP4) occur in seronegative AChR-negative cases and are associated with distinct clinical phenotypes.
• Neuromuscular junction changes:
  • Loss and simplification of postsynaptic folds.
  • Reduced number of functional ACh receptors.
  • Widened synaptic cleft and complement-mediated structural damage.
• Thymus involvement:
  • The thymus plays a central role in the pathogenesis of many MG subtypes, with thymic hyperplasia or thymoma driving autoimmunity.

The net effect is failure to reliably generate an action potential in muscle fibers during sustained activity, explaining the hallmark fatigability and fluctuation of symptoms. [1](https://europepmc.org/article/MED/41607837)

Clinical Presentation

MG presents with fluctuating, fatigable weakness of skeletal muscles that typically worsens with exertion and improves with rest. Patterns of involvement vary, but certain features are characteristic. [1](https://europepmc.org/article/MED/41607837) [3](https://europepmc.org/article/MED/41462932)

• Ocular symptoms (most common initial presentation):
  • Ptosis (often asymmetric, may shift sides).
  • Diplopia due to extraocular muscle weakness.
  • Symptoms worsen later in the day or with prolonged upgaze.
• Bulbar symptoms:
  • Dysarthria (nasal or slurred speech).
  • Dysphagia (difficulty swallowing, choking episodes).
  • Fatigable chewing, especially with tough foods.
• Facial and neck weakness:
  • Facial diplegia with "myasthenic snarl" or flattened smile.
  • Neck flexor weakness leading to head drop.
• Limb weakness:
  • Predominantly proximal, affecting tasks like climbing stairs, combing hair, or lifting objects.
  • Often asymmetric and fatigable.
• Respiratory involvement:
  • Weakness of respiratory muscles may cause dyspnea and predispose to myasthenic crisis.

Sensory examination, reflexes, and autonomic function are characteristically normal, which helps distinguish MG from many other neuromuscular disorders.

Myasthenic Crisis

Myasthenic crisis is an acute exacerbation of MG with severe weakness of respiratory and/or bulbar muscles leading to respiratory failure or inability to protect the airway. It is a neurologic emergency and often triggered by infection, surgery, certain medications, or inadequate immunosuppression. [1](https://europepmc.org/article/MED/41607837)

Diagnosis

Diagnosis of MG integrates clinical assessment, serologic testing, electrophysiology, and imaging of the mediastinum (to assess the thymus). Recent work has emphasized standardized clinical scoring systems to quantify disease severity and response to treatment. [3](https://europepmc.org/article/MED/41462932)

1. Clinical Evaluation

• History: Fluctuating weakness, fatigability, diurnal variation, distribution of symptoms (ocular, bulbar, limb, respiratory), triggers (heat, infection, medications).
• Examination:
  • Fatigable ptosis with sustained upgaze.
  • Worsening diplopia with repeated eye movements.
  • Fatigable limb and neck weakness with repetitive testing.

2. Serologic Testing

• AChR antibodies: Positive in the majority of generalized MG and many ocular MG cases; strongly supportive of diagnosis. [3](https://europepmc.org/article/MED/41462932)
• MuSK antibodies: Assessed when AChR antibodies are negative; associated with prominent bulbar and respiratory involvement and often more severe disease.
• Other antibodies (e.g., LRP4) may be present in some seronegative cases.

3. Electrophysiologic Studies

• Repetitive nerve stimulation (RNS):
  • Demonstrates a decremental response (usually >10% drop in compound muscle action potential amplitude) with low-frequency stimulation.
• Single-fiber EMG (SFEMG):
  • Highly sensitive; shows increased "jitter" and blocking, reflecting impaired neuromuscular transmission.

4. Pharmacologic and Bedside Tests

• Edrophonium (Tensilon) test (historical/limited use): Transient improvement in weakness after short-acting acetylcholinesterase inhibitor; now less used due to side effects and availability of better diagnostics.
• Ice pack test for ptosis: Improvement of ptosis after application of ice over the eyelids for several minutes supports a diagnosis of MG (safe and practical bedside test).

5. Imaging

• Chest CT or MRI is indicated to evaluate for thymic hyperplasia or thymoma, as thymic pathology guides management decisions (e.g., thymectomy).

6. Disease Severity Scores

Standardized MG scores (e.g., MG-ADL, QMG) are used in clinical trials and can help track symptoms and treatment response, forming the basis for modeling disease and potential digital twin approaches in MG. [3](https://europepmc.org/article/MED/41462932)

Management

Management of MG includes symptomatic therapy, immunomodulating treatment, crisis management, and treatment of associated thymic disease. Care is individualized based on antibody status, distribution and severity of weakness, comorbidities, and patient preferences. [1](https://europepmc.org/article/MED/41607837) [3](https://europepmc.org/article/MED/41462932)

1. Symptomatic Treatment

• Acetylcholinesterase inhibitors (e.g., pyridostigmine):
  • Increase synaptic acetylcholine by inhibiting its breakdown.
  • Improve muscle strength and reduce fatigability, especially in mild or predominantly ocular disease.
  • Dose is titrated to symptom control, limited by cholinergic side effects (GI upset, increased secretions, cramps).

2. Immunosuppressive Therapy

• Corticosteroids:
  • Prednisone is commonly used to induce remission or significant improvement.
  • Initial exacerbation of weakness can occur; dosing and titration strategies vary to minimize this risk.
• Steroid-sparing agents:
  • Azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, and others can be used for long-term immunosuppression to reduce steroid exposure.
  • Onset of action may be delayed for months, requiring bridging strategies.
• Targeted biologic therapies:
  • Monoclonal antibodies and complement inhibitors (e.g., those targeting the complement cascade or B cells) have emerged in recent years and are particularly important for refractory disease, as reflected in contemporary MG management strategies. [3](https://europepmc.org/article/MED/41462932)

3. Rapid Immunomodulation

• Plasmapheresis (PLEX) and intravenous immunoglobulin (IVIG):
  • Used for rapid improvement in patients with myasthenic crisis, severe exacerbations, or preoperatively before thymectomy.
  • Provide temporary benefit by removing or neutralizing pathogenic antibodies.

4. Thymectomy

• Indications:
  • All patients with thymoma, regardless of MG severity, typically require surgical resection.
  • Selected patients with non-thymomatous, generalized AChR-positive MG may benefit from thymectomy, with data supporting improved clinical outcomes in appropriately chosen patients.
• Role: Thymectomy aims to reduce autoimmunity and can lead to remission or reduced need for immunosuppressive therapy in some patients.

5. Management of Myasthenic Crisis

• Requires intensive monitoring of respiratory function and airway protection.
• Rapid immunomodulatory therapy (PLEX or IVIG) is initiated.
• Optimize chronic immunosuppression and identify/treat triggers (e.g., infection, medication changes).

6. Patient-Centered and Multidisciplinary Care

Recent work has emphasized the value of patient-centric, immersive learning programs and multidisciplinary approaches for optimizing MG care, highlighting the impact of MG on quality of life and the need for education of both clinicians and patients. [1](https://europepmc.org/article/MED/41607837)

Key Clinical Pearls

• Fluctuating, fatigable weakness with normal sensation and reflexes is the hallmark of MG.
• Ocular MG (isolated ptosis/diplopia) is a common initial presentation; many patients later generalize.
• Myasthenic crisis is a life-threatening exacerbation with respiratory or bulbar failure and demands rapid intervention.
• AChR antibodies are highly specific; negative serology does not exclude MG, especially in cases with MuSK or other antibodies. [3](https://europepmc.org/article/MED/41462932)
• Single-fiber EMG is the most sensitive test for neuromuscular junction transmission defects.
• Thymic imaging (CT/MRI) is mandatory to exclude thymoma in all generalized MG patients.
• Certain drugs (e.g., some antibiotics, neuromuscular blockers, magnesium, beta-blockers) can worsen MG and should be used cautiously or avoided.
• Long-term management combines symptomatic treatment and immunosuppression, with newer biologic agents reserved for refractory or severe disease. [1](https://europepmc.org/article/MED/41607837)
• Standardized MG scores are increasingly important for monitoring disease and guiding evidence-based care and research, including digital twin modeling. [3](https://europepmc.org/article/MED/41462932)

Summary

Myasthenia gravis is a prototypical autoimmune neuromuscular junction disorder characterized by fluctuating weakness due to antibody-mediated impairment of neuromuscular transmission. Diagnosis relies on recognizing the clinical pattern, confirming with serology and electrophysiology, and evaluating for thymic pathology. Management requires a combination of symptomatic therapy, immunosuppression, rapid immunomodulation for crises, and surgical thymectomy in selected patients. A patient-centered, multidisciplinary approach and use of validated MG severity scores are central to modern MG care and research. [1](https://europepmc.org/article/MED/41607837) [3](https://europepmc.org/article/MED/41462932)